Xeolas officially launches its 158,000 square foot state of the art facility in Baldoyle

New Dublin facility strengthens Irish-owned company’s capacity to develop and manufacture innovative medicines at scale for patients with unmet needs

Irish-owned specialty pharmaceutical company Xeolas Pharmaceuticals has officially opened its new state-of-the-art facility in Baldoyle, Dublin, further strengthening its ability to develop and manufacture patient-friendly medicines for both domestic and international markets.

The new facility brings together pharmaceutical research, development, manufacturing and regulatory capabilities and has been designed to support Xeolas’ continued growth. The site and surrounding location offer significant potential for future expansion as global demand grows for innovative treatments addressing unmet patient needs.

Founded in Ireland in 2007 by pharmacist and pharmaceutical executive Damien Flynn, Xeolas now employs more than 100 people. The company specialises in reimagining proven medicines to create smarter, patient-centric reformulations, particularly for patient groups whose needs may be overlooked by traditional drug-development models. Xeolas is already present in 21 countries worldwide which will continue to grow as it brings to market the pipeline which consists of over 25 products with many at a late stage of development. 

Damien Flynn, Founder and Chief Executive Officer of Xeolas Pharmaceuticals, said: “The opening of our new facility is an important milestone for Xeolas and reflects the ambition, expertise and commitment of our entire team. The progress we have made as a company has been driven by the quality of our people and the depth of scientific, clinical, regulatory and commercial expertise we have in our team. This new facility gives them the capacity to advance more innovative medicines from development through to commercial supply, while creating a strong platform for our next phase of growth.

“Our focus is firmly on patients. By building on established medicines and existing clinical evidence, we can move faster and reduce development risk while delivering meaningful new treatment options for people with unmet needs.”                  

Leo McAdams, Head of Advanced Manufacturing, Construction and Lifesciences at Enterprise Ireland said, “Xeolas Pharmaceuticals is at the forefront of innovation in the pharma sector, developing and enhancing medicines to meet patient needs in this critical sector. I’d like to congratulate the team on today’s new office opening. Supporting Irish companies with the ambition to scale globally is a key priority for Enterprise Ireland and we look forward to working closely with Xeolas to optimise their full international growth potential, creating and sustaining jobs here in Ireland.”

Xeolas develops innovative formulations of established active substances and manages the full pharmaceutical value chain, from formulation and clinical development to regulatory submission, manufacturing and commercial supply. Products developed by the company are approved in major European markets and are marketed by its partners across Europe and internationally.

The company’s expanded operations reinforce Ireland’s position as a centre of excellence for pharmaceutical innovation, advanced manufacturing and highly skilled employment.

Ends

Issued by Walsh on behalf of Xeolas Contact: Maeve Governey Maeve@walshpr.ie

Notes to editors

• Xeolas Pharmaceuticals is an Irish-owned specialty pharmaceutical company founded in 2007.
• The company employs more than 100 people in Ireland.
• Xeolas develops and manufactures innovative, patient-friendly medicines for international markets.
• Its approach combines established active substances and existing clinical evidence with innovative formulations to address unmet patient needs.
• Xeolas’ commercial products include Pedippi®, an oral omeprazole formulation developed for children, and Bonasol®, a drinkable alendronic acid solution.
• Further information is available at www.xeolas.com.